Top

Published in:

Open Access 01-12-2023 | Lymphoma | Research

Peripheral immune cell profiling of double-hit lymphoma by mass cytometry

Authors: Tao Lei, Gongqiang Wu, Yongjin Xu, Weihao Zhuang, Jialiang Lu, Shuiyun Han, Yuxin Zhuang, Xiaowu Dong, Haiyan Yang

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Double-hit or Triple-hit lymphoma (DHL/THL) is a subset of high-grade B cell lymphoma harboring rearrangements of MYC and BCL2 and/or BCL6, and usually associate with aggressive profile, while current therapies tend to provide poor clinical outcomes and eventually relapsed. Further explorations of DHL at cellular and molecular levels are in demand to offer guidance for clinical activity.

Methods

We collected the peripheral blood of DHL patients and diffused large B cell lymphoma (DLBCL) patients from single institute and converted them into PBMC samples. Mass cytometry was then performed to characterize these samples by 42 antibody markers with samples of healthy people as control. We divided the immune cell subtypes based on the expression profile of surface antigens, and the proportion of each cell subtype was also analyzed. By comparing the data of the DLBCL group and the healthy group, we figured out the distinguished immune cell subtypes of DHL patients according to their abundance and marker expression level. We further analyzed the heterogeneity of DHL samples by pairwise comparison based on clinical characteristics.

Results

We found double-positive T cells (DPT) cells were in a significantly high percentage in DHL patients, whereas the ratio of double-negative T cells (DNT) was largely reduced in patients. Besides, CD38 was uniquely expressed at a high level on some naïve B cells of DHL patients, which could be a marker for the diagnosis of DHL (distinguishing from DLBCL), or even be a drug target for the treatment of DHL. In addition, we illustrated the heterogeneity of DHL patients in terms of immune cell landscape, and highlighted TP53 as a major factor that contributes to the heterogeneity of the T cells profile.

Conclusion

Our study demonstrated the distinct peripheral immune cell profile of DHL patients by contrast to DLBCL patients and healthy people, as well as the heterogeneity within the DHL group, which could provide valuable guidance for the diagnosis and treatment of DHL.

Available only for authorised users

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569.CrossRefPubMedPubMedCentral

Zhuang Y, Che J, Wu M, Guo Y, Xu Y, Dong X, Yang H. Altered pathways and targeted therapy in double hit lymphoma. J Hematol Oncol. 2022;15(1):26. https://doi.org/10.1186/s13045-022-01249-9.CrossRefPubMedPubMedCentral

Dunleavy K. Double-hit lymphoma: optimizing therapy, Hematology Am Soc Hematol Educ Program 2021; 2021(1): 157–163. doi: https://doi.org/10.1182/hematology.2021000247.

Roth CG, Gillespie-Twardy A, Marks S, Agha M, Raptis A, Hou J, Farah R, Lin Y, Qian Y, Pantanowitz L, Boyiadzis M. Flow Cytometric evaluation of Double/Triple hit Lymphoma. Oncol Res. 2016;23:137–46. https://doi.org/10.3727/096504015X14500972666761.CrossRefPubMedPubMedCentral

Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, et al. Double-hit Gene expression signature defines a distinct subgroup of Germinal Center B-Cell-Like diffuse large B-Cell lymphoma. J Clin Oncol. 2018;37(3):190–201. https://doi.org/10.1200/JCO.18.01583.CrossRefPubMedPubMedCentral

Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, Kennedy H, et al. Molecular High-Grade B-Cell Lymphoma: defining a poor-risk group that requires different approaches to Therapy. J Clin Oncol. 2018;37(3):202–12. https://doi.org/10.1200/JCO.18.01314.CrossRefPubMedPubMedCentral

Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang I, Fleener C. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? J Immunother Cancer. 2019;7:325. https://doi.org/10.1186/s40425-019-0799-2.CrossRefPubMedPubMedCentral

Araujo B, de Lima V, Hansen M, Spanggaard I, Rohrberg K, Hadrup SR, Lassen U, Svane IM. Immune Cell profiling of peripheral blood as signature for response during checkpoint inhibition Across Cancer types. Front Oncol. 2021;11:558248. https://doi.org/10.3389/fonc.2021.558248.CrossRef

Bruss C, Kellner K, Ortmann O, Seitz S, Brockhoff G, Hutchinson J, Wege AK. Advanced Immune Cell profiling by Multiparameter Flow Cytometry in Humanized patient-derived Tumor mice. Cancers. 2022;14(9):2214. https://doi.org/10.3390/cancers14092214.CrossRefPubMedPubMedCentral

10.

Yang Z, Kim HJ, Villasboas JC, Price-Troska T, Jalali S, Wu H, Luchtel RA, Polley MC, Novak AJ, Ansell SM. Mass Cytometry Analysis reveals that specific Intratumoral CD4⁺ T cell subsets correlate with patient survival in follicular lymphoma. Cell Rep. 2019;26(8):2178–2193e3. https://doi.org/10.1016/j.celrep.2019.01.085.CrossRefPubMedPubMedCentral

11.

Merdan S, Subramanian K, Ayer T, Weyenbergh JV, Chang A, Koff JL, Flowers C. Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma. Blood Cancer J. 2021;11(1):2. https://doi.org/10.1038/s41408-020-00404-0.CrossRefPubMedPubMedCentral

12.

Amini RM, Enblad G, Hollander P, Laszlo S, Eriksson E, Gustafsson KA, Loskog A, Thörn I. Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients. BMC Cancer. 2019;19(1):316. https://doi.org/10.1186/s12885-019-5529-0.CrossRefPubMedPubMedCentral

13.

Amir ED, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, Shenfeld DK, Krishnaswamy S, Nolan GP. Pe’er D, viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol. 2013;31(6):545–52. https://doi.org/10.1038/nbt.2594.CrossRefPubMedPubMedCentral

14.

Salumets A, Tserel L, Rumm AP, Türk L, Kingo K, Saks K, Oras A, Uibo R, et al. Epigenetic quantification of immunosenescent CD8⁺ TEMRA cells in human blood. Aging Cell. 2022;21(5):e13607. https://doi.org/10.1111/acel.13607.CrossRefPubMedPubMedCentral

15.

Gallou SL, Lhomme F, Irish JM, Mingam A, Pangault C, Monvoisin C, Ferrant J, et al. Nonclassical monocytes are Prone to migrate into tumor in diffuse large B-Cell lymphoma. Front Immunol. 2021;12:755623. https://doi.org/10.3389/fimmu.2021.755623.CrossRefPubMedPubMedCentral

16.

Li H, Burgueño-Bucio E, Xu S, Das S, Olguin-Alor R, Elmets CA, Athar M, Raman C, Soldevila G, Xu H. CD5 on dendritic cells regulates CD4⁺ and CD8⁺ T cell activation and induction of immune responses. PLoS ONE. 2019;14(9):e0222301. https://doi.org/10.1371/journal.pone.0222301.CrossRefPubMedPubMedCentral

17.

Mount AM, Smith CM, Kupresanin F, Stoermer K, Heath WR, Belz GT. Multiple dendritic cell populations activate CD4⁺ T cells after viral stimulation. PLoS ONE. 2008;3(2):e1691. https://doi.org/10.1371/journal.pone.0001691.CrossRefPubMedPubMedCentral

18.

Sconocchia G, Titus JA, Mazzoni A, Visintin A, Pericle F, Hicks SW, Malavasi F, Segal DM. CD38 triggers cytotoxic responses in activated human natural killer cells. Blood. 1999;94(11):3864–71. https://doi.org/10.1182/blood.V94.11.3864.CrossRefPubMed

19.

Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A. 1999;96(10):5640–4. https://doi.org/10.1073/pnas.96.10.5640.CrossRefPubMedPubMedCentral

20.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Barreto I, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms, Leukemia 2022; 36: 1720–1748. doi.10.1038/s41375-022-01620-2.

21.

Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000;6(7):782–9. https://doi.org/10.1038/77513.CrossRefPubMed

22.

Rensing-Ehl A, Völkl S, Speckmann C, Lorenz MR, Ritter J, Janda A, Abinun M, Pircher H, et al. Abnormally differentiated CD4⁺ or CD8⁺ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency. Blood. 2014;124(6):851–60. https://doi.org/10.1182/blood-2014-03-564286.CrossRefPubMed

23.

Zhang Z, Yang L, Young KJ, Zhang L. Suppression of alloimmune responses in vitro and in vivo by CD3(+) CD8(-) CD4(-) alphabeta(+) regulatory T cells. Transplant Proc. 2001; 33(1–2): 84–85. doi: https://doi.org/10.1016/s0041-1345(00)01915-1.

24.

Chen W, Ford MS, Young KJ, Cybulsky MI, Zhang L. Role of double-negative regulatory T cells in long-term cardiac xenograft survival. J Immunol. 2003;170(4):1846–53. https://doi.org/10.4049/jimmunol.170.4.1846.CrossRefPubMed

25.

Yao J, Ly D, Dervovic D, Fang L, Lee JB, Kang H, Wang Y, Pham N, Pan H, Tsao M, Zhang L. Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. J Immunother Cancer. 2019;7(1):17. https://doi.org/10.1186/s40425-019-0507-2.CrossRefPubMedPubMedCentral

26.

Merims S, Li X, Joe B, Dokouhaki P, Han M, Childs RW, Wang Z, Gupta V, Minden MD, Zhang L. Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy. Leukemia. 2011;25(9):1415–22. https://doi.org/10.1038/leu.2011.99.CrossRefPubMedPubMedCentral

27.

Lee J, Minden M, Chen W, Streck E, Chen B, Kang H, Arruda A, Ly D, et al. Allogeneic human double negative T cells as a Novel Immunotherapy for Acute myeloid leukemia and its underlying mechanisms. Clin Cancer Res. 2018;24(2):370–82. https://doi.org/10.1158/1078-0432.CCR-17-2228.CrossRefPubMed

28.

Fang L, Ly D, Wang S, Lee JB, Kang H, Xu H, Yao J, Tsao M, Liu W, Zhang L. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. J Exp Clin Cancer Res. 2019;38(1):123. https://doi.org/10.1186/s13046-019-1126-y.CrossRefPubMedPubMedCentral

29.

Desfrançois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, Dréno B, Jotereau F, Gervois N. Double positive CD4/CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. PLoS ONE. 2010;5(1):e8437. https://doi.org/10.1371/journal.pone.0008437.CrossRefPubMedPubMedCentral

30.

Zhong C, Song Z, Li M. Gastric cancer patients display a distinctive population of IFNg⁺ IL10⁺ double positive CD8 T cells, which persists longer during prolonged activation. Exp Cell Res. 2019;382(2):111487. https://doi.org/10.1016/j.yexcr.2019.06.032.CrossRefPubMedPubMedCentral

31.

Bohner P, Chevalier MF, Cesson V, Rodrigues-Dias S, Dartiguenave F, Burruni R, Tawadros T, et al. Double positive CD4⁺ CD8⁺ T cells are enriched in Urological Cancers and Favor T Helper-2 polarization. Front Immunol. 2019;10:622. https://doi.org/10.3389/fimmu.2019.00622.CrossRefPubMedPubMedCentral

32.

Wada F, Shimomura Y, Yabushita T, Yamashita D, Ohno A, Imoto H, Maruoka H, Hara S, Ishikawa T. CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma. Hematol Oncol. 2021;39(4):483–9. https://doi.org/10.1002/hon.2904.CrossRefPubMed

33.

Ibrahim S, Keating M, Do KA, O’Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98(1):181–6. https://doi.org/10.1182/blood.v98.1.181.CrossRefPubMed

34.

Vockova P, Svaton M, Karolova J, Pokorna E, Vokurka M, Klener P. Anti-CD38 therapy with Daratumumab for Relapsed/Refractory CD20-Negative diffuse large B-Cell lymphoma. Folia Biol (Praha). 2020;66(1):17–23.PubMed

35.

Puchner A, Saferding V, Bonelli M, Mikami Y, Hofmann M, Brunner JS, et al. Non-classical monocytes as mediators of tissue destruction in arthritis. Ann Rheum Dis. 2018;77(10):1490–7. https://doi.org/10.1136/annrheumdis-2018-213250.CrossRefPubMed

36.

Kapellos TS, Bonaguro L, Gemünd I, Reusch N, Saglam A, Hinkley ER, Schultze JL. Human monocyte subsets and phenotypes in Major Chronic Inflammatory Diseases. Front Immunol. 2019;10:2035. https://doi.org/10.3389/fimmu.2019.02035.CrossRefPubMedPubMedCentral

37.

Hou H, Luo Y, Tang G, Zhang B, Ouyang R, Wang T, Huang M, Wu S, Li D, Wang F. Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy. Cancer Cell Int. 2021;21(1):282. https://doi.org/10.1186/s12935-021-01978-w.CrossRefPubMedPubMedCentral

38.

Bezzi M, Seitzer N, Ishikawa T, Reschke M, Chen M, Wang G, Mitchell C, Ng C, Katon J, Lunardi A et al. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.Nat Med. 2018;24:165–175. doi: https://doi.org/10.1038/nm.4463.

39.

Kawashima H, Takatori H, Suzuki K, Iwata A, Yokota M, Suto A, Minamino T, Hirose K, Nakajima H. Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells. J Immunol. 2013;191(7):3614–23. https://doi.org/10.4049/jimmunol.1300509.CrossRefPubMed

40.

Cao Z, Kon N, Liu Y, Xu W, Wen J, Yao H, Zhang M, Wu Z, Yan X, Zhu W, Gu W, Wang D. An unexpected role for p53 in regulating cancer cell-intrinsic PD-1 by acetylation. Sci Adv. 2021;7(14):eabf4148. https://doi.org/10.1126/sciadv.abf4148.CrossRefPubMedPubMedCentral

41.

Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino M, Panizo C, Hervas-Stubbs S, Alignani D, Sagardoy A, Martinez-Ferrandis JI, et al. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019;133(22):2401–12. https://doi.org/10.1182/blood.2018889931.CrossRefPubMedPubMedCentral

42.

Zhang Z, Hao R, Guo Q, Zhang S, Wang X. TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer, Front Cell Dev Biol. 2021; 9: 759154. doi: https://doi.org/10.3389/fcell.2021.759154.

43.

Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou H, Eksioglu EA, Sullivan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136(24):2812–23. https://doi.org/10.1182/blood.2020006158.CrossRefPubMedPubMedCentral

Title: Peripheral immune cell profiling of double-hit lymphoma by mass cytometry
Authors: Tao Lei
Gongqiang Wu
Yongjin Xu
Weihao Zhuang
Jialiang Lu
Shuiyun Han
Yuxin Zhuang
Xiaowu Dong
Haiyan Yang
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Lymphoma
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10657-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Refining gastric cancer staging: examining the interplay between number and anatomical location of metastatic lymph nodes - a retrospective multi-institutional study

HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)—study protocol of a randomised healthcare policy trial

Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial): a study protocol for a stepped-wedge cluster-randomised trial

Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis

Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression

EOAI, a ubiquitin-specific peptidase 5 inhibitor, prevents non-small cell lung cancer progression by inducing DNA damage

Keynote webinar | Spotlight on antibody–drug conjugates in cancer